



4-14-04
Imake

1632\$
PTO/SB/21 (08-03)

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	09/723,713
		Filing Date	November 27, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1632
		Examiner Name	Anne Marie Sabrina Wehbe
Total Number of Pages in This Submission	11	Attorney Docket Number	15270J-004741US

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement (5 pp) w/attached 8A (1 pp.) & 08B (2 pp.) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i> Cited references 407-442*; and, Return Postcard
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.
* not included in "Total Number of Pages in this Submission"		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Townsend and Townsend and Crew LLP Rosemarie L. Celli Reg. No. 42,397
Signature	<i>Rosemarie L. Celli</i>
Date	April 12, 2004

CERTIFICATE OF MAILING		
Express Mail Label: EV 338 446 263 I hereby certify that this correspondence is being deposited with the United States Postal Service with "Express Mail Post Office to Address" service under 37 CFR 1.10 on this date Ron Anton and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450		
Typed or printed name	Ron Anton	
Signature	<i>Ron Anton</i>	Date April 12, 2004



FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180

Complete if Known

Application Number	09/723,713
Filing Date	November 27, 2000
First Named Inventor	Schenk, Dale B.
Examiner Name	Anne Marie Sabrina Wehbe
Art Unit	1632
Attorney Docket No.	15270J-004741US

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit
Account
Number

20-1430

Deposit
Account
Name

Townsend and Townsend and Crew LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1)

(\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims	Fee from below	Fee Paid
Total Claims	<input type="text"/>	<input type="text"/>	<input type="text"/>
Independent Claims	<input type="text"/>	<input type="text"/>	<input type="text"/>
Multiple Dependent	<input type="text"/>	<input type="text"/>	<input type="text"/>

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)

(\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Petitions related to provisional applications	
1806	180	1806	180	Submission of Information Disclosure Stmt	180
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid SUBTOTAL (3)

(\$180)

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Rosemarie L. Celli	Registration No. (Attorney/Agent)	42,397	Telephone	650-326-2400
Signature	Rosemarie L. Celli			Date	April 12, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.



PATENT
Attorney Docket No.: 15270J-004741US
Client Reference No.: 209-US-CIP5C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk

Application No.: 09/723,713

Filed: November 27, 2000

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Anne Marie Sabrina Wehbe

Art Unit: 1632

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicant also cites commonly owned copending applications directed to related subject matter:

09/201,430 filed 11/30/98 issue fee paid on 10/07/03;
09/497,553 filed 02/03/00;
09/724,477 filed 11/28/00 issue fee paid on 10/07/03;
09/723,927 filed 11/28/00 issue fee paid on 10/07/03;
09/723,762 filed 11/28/00 issue fee paid on 10/07/03;
09/724,102 filed 11/28/00 issue fee paid on 10/07/03;
09/724,489 filed 11/28/00 issue fee paid on 10/07/03;
15270J-004727US filed 03/31/04;

04/14/2004 SSESHE1 00000111 201430 09723713
01 FC:1806 180.00 DA

15270J-004728US filed 03/31/04;
15270J-004729US filed 03/31/04;
15270J-004733US filed 03/31/04;
15270J-004736US filed 03/31/04;
15270J-004738US filed 03/31/04;
09/322,289 filed 05/28/99;
09/723,713 filed 11/27/00;
09/723,760 filed 11/27/00;
09/724,319 filed 11/27/00;
09/723,384 filed 11/27/00 issued as U.S. 6,710,226 on 03/23/04;
09/724,495 filed 11/27/00;
10/788,666 filed 02/27/04;
10/429,216 filed 05/30/03;
09/580,015 filed 05/26/00;
09/724,940 filed 11/28/00;
09/724,961 filed 11/28/00 issue fee paid on 02/26/04;
09/580,018 filed 05/26/00 issue fee paid on 02/26/04;
09/724,552 filed 11/28/00 issue fee paid on 02/26/04;
09/723,544 filed 11/28/00;
09/724,273 filed 11/28/00;
09/724,551 filed 11/28/00; issue fee paid on 02/26/04;
09/724,288 filed 11/28/00;
10/777,792 filed 02/11/04;
15270J-004767US filed 04/12/04;
09/580,019 filed 05/26/00;
09/723,765 filed 11/28/00;
09/724,291 filed 11/28/00;
09/724,929 filed 11/28/00;
09/585,817 filed 06/01/00;
09/724,567 filed 11/28/00 notice of allowance mailed 03/02/04;

09/724,575 filed 11/28/00;
09/724,953 filed 11/28/00 notice of allowance mailed 03/11/04;
09/724,570 filed 11/28/00;
09/585,656 filed 06/01/00;
09/723,766 filed 11/27/00;
09/723,725 filed 11/27/00;
09/579,690 filed 05/26/00;
09/979,701 filed 03/13/01 (U.S. Nat'l Stage of PCT/US00/14810 filed 05/26/00);
09/979,952 filed 04/04/02 (U.S. Nat'l Stage of PCT/US00/15239 filed 06/01/00);

and,

09/980,568 filed 03/12/02 (U.S. Nat'l Stage of PCT/US00/15302 filed 06/01/00).

Applicant also cites the following copending applications directed to related subject matter but subject to different assignment:

10/010,942 filed 12/06/01;
10/789,273 filed 2/27/04;
10/232,030 filed 08/30/02;
10/388,389 filed 03/12/03
10/703,713 filed November 7, 2003
10/704,070 filed November 7, 2003
10/388,214 filed 03/12/03;
60/474,654 filed 05/30/03;
60/530,481 filed 12/17/03; and,
10/771,174 filed 02/04/04.

Applicant further cites the following commonly owned abandoned applications directed to related subject matter:

60/067,740 filed 12/02/97;
60/080,970 filed 04/07/98;
60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;

09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00;
60/137,010 filed 06/01/99;
60/251,892 filed 12/6/00;
60/137,047 filed 06/01/99; and,
60/136,655 filed 05/28/99.

Applicant also cites the following abandoned application directed to related subject matter but subject to different assignment:

60/251,892 filed 12/06/00;
60/444,150 filed 02/01/03; and,
60/363,751 filed 03/12/02.

Applicant points out that the following applications are now commonly assigned but were previously subject to different assignment than the present application:

60/067,219 filed 12/03/97;
60/079,697 filed 03/27/98;
09/204,838 filed 12/03/98;
09/724,921 filed 11/28/00; and,
09/724,929 filed 11/28/00.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Dale B. Schenk
Application No.: 09/723,713
Page 5

PATENT

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.


Respectfully submitted,



Rosemarie L. Celli
Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
RLC:crf

60186148 v1




Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/723,713	
			Filing Date	November 27, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1632	
			Examiner Name	Anne Marie Sabrina Wehbe	
			Attorney Docket Number	15270J-004741US	
Sheet	2	of	3		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	418	BORK, P., "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <u>Genome Research</u> , 10:398-400 (2000)	
	419	BORK et al., "Go hunting in sequence databases but watch out for the traps," <u>Trends in Genetics</u> , 12(10):425-427 (1996).	
	420	BRENNER, S. E., "Errors in genome annotation," <u>Trends in Genetics</u> , 15(4):132-133 (1999).	
	421	CASTILLO et al., "Amylin / Islet Amyloid Polypeptide: Biochemistry, Physiology, Patho-Physiology," <u>Diabete & Metabolisme (Paris)</u> , 21:3-25 (1995).	
	412	DAS et al., "Amyloid- β Immunization Effectively Reduces Amyloid Deposition in FcR γ Knock-Out Mice," <u>J. Neuroscience</u> , 23(24):8532-8538 (2003).	
	436	DICKSON et al., "Neuroimmunology of Alzheimer's disease: a conference report," <u>Neurobiology of Aging</u> , 13(6):793-798 (1992), abstract only	
	422	DOERKS et al., "Protein annotation: detective work for function prediction," <u>Trends in Genetics</u> , 14(6):248-250 (1998).	
	407	ECK et al., <i>Goodman and Gilman's The pharmacological basis of therapeutics</i> , Chapter 5, pages 77-101 (1996)	
	423	FONSECA et al., "The Presence of Isoaspartic Acid in β -Amyloid Plaques Indicates Plaque Age," <u>Experimental Neurology</u> , 157(2):277-288 (1999).	
	424	GOLDSBY et al., "Vaccines," Chapter 18 from <i>Immunology, 4th Edition</i> , W.H. Freeman and Company, New York, pages 449-465.	
	413	HOLTZMAN et al., "A β immunization and anti-A β antibodies: potential therapies for the prevention and treatment of Alzheimer's disease," <u>Advanced Drug Delivery Reviews</u> , 54:1603-1613 (2002).	
	434	KELLY, J. W., "Alternative conformations of amyloidogenic proteins govern their behavior," <u>Current Opinion in Structural Biology</u> , 6:11-17 (1996).	
	408	MARSHALL, E., "Gene Therapy's Growing Pains," <u>Science</u> , 269:1050-1055 (1995).	
	439	NALBANTOGLU, J., "Beta-amyloid protein in Alzheimer's disease," <u>Can. J. Neurol. Sci.</u> , 18(3 suppl.):424-427 (1991), abstract only	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/723,713	
			Filing Date	November 27, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1632	
			Examiner Name	Anne Marie Sabrina Wehbe	
Sheet	3	of	3	Attorney Docket Number	15270J-004741US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	425	NGO et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," pages 492-495 from Chapter 14 of <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , Merz et al., eds., Birkhauser Boston (1994).	
	409	ORKIN et al., <i>Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy</i> , December 7, 1995	
	437	PERSSON et al., "IgG subclass-associated affinity differences of specific antibodies in humans," <i>J. Immunology</i> , 140(11):3875-3879 (1988), abstract only	
	414	SCHENK, D., "Amyloid- β immunotherapy for Alzheimer's disease: the end of the beginning," <i>Nature Reviews</i> , 3:824-828 (2002).	
	426	SINGH, K. S., "Neuroautoimmunity: Pathogenic Implications for Alzheimer's Disease," <i>Gerontology</i> , 43:79-94 (1997).	
	438	SINGH, V. K., "Studies of neuroimmune markers in Alzheimer's disease," <i>Mol. Neurobiology</i> , 9(1-3):73-81 (1994), abstract only	
	427	SMITH et al., "The challenges of genome sequence annotation or 'The devil is in the details,'" <i>Nature Biotechnology</i> , 15:1222-1223 (1997).	
	411	SOLOMON et al., "The Amino Terminus of the β -Amyloid Peptide Contains an Essential Epitope for Maintaining Its Solubility," from <i>Progress in Alzheimer's and Parkinson's Diseases</i> , edited by Fisher et al., Plenum Press, New York, pages 205-211 (1995).	
	435	STERN et al., "Antibodies to the β -amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood," <i>FEBS Letters</i> , 264(1):43-47 (1990).	
	428	VELAZQUEZ et al., "Aspartate residue 7 in amyloid β -protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis," <i>Nature Medicine</i> , 3(1):77-79 (1997).	
	410	VERMA et al., "Gene therapy - promises, problems and prospects," <i>Nature</i> , 389:239-242 (1997).	
	429	WELLS, J. A., "Additivity of Mutational Effects in Proteins," <i>Biochemistry</i> , 29(37):8509-8517 (1990).	
	430	YANG et al., "Effects of Racemization on the Aggregational Properties of the Amyloid β -Peptide in Alzheimer's Disease," abstract # 255 from American Chemical Society 214th National Meeting (1997).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.